Hanall Biopharma Past Earnings Performance

Past criteria checks 0/6

Hanall Biopharma's earnings have been declining at an average annual rate of -49.6%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 7.5% per year.

Key information

-49.6%

Earnings growth rate

-49.5%

EPS growth rate

Pharmaceuticals Industry Growth	11.3%
Revenue growth rate	7.5%
Return on equity	-3.7%
Net Margin	-4.7%
Last Earnings Update	30 Sep 2024

Recent past performance updates

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Recent updates

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21

Revenue & Expenses Breakdown

How Hanall Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A009420 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	134,245	-6,288	51,280	23,280
30 Jun 24	130,374	-6,191	50,900	21,898
31 Mar 24	140,199	4,439	49,768	23,304
31 Dec 23	134,910	3,509	48,039	23,945
30 Sep 23	133,308	6,049	46,106	23,701
30 Jun 23	129,981	6,464	44,765	23,374
31 Mar 23	114,812	-919	43,862	19,276
31 Dec 22	109,995	251	42,647	16,498
30 Sep 22	104,764	-376	41,420	13,877
30 Jun 22	100,596	949	39,801	12,236
31 Mar 22	97,783	4,288	38,883	11,089
31 Dec 21	101,594	8,896	38,450	10,462
30 Sep 21	98,500	16,123	37,455	10,238
30 Jun 21	95,140	17,778	36,391	9,783
31 Mar 21	94,304	20,413	35,412	9,789
31 Dec 20	88,602	19,765	34,137	9,316
30 Sep 20	92,953	19,714	33,781	8,018
30 Jun 20	98,834	21,457	33,991	8,769
31 Mar 20	106,049	19,753	34,243	9,279
31 Dec 19	108,452	19,174	34,274	10,051
30 Sep 19	105,550	10,279	34,952	10,263
30 Jun 19	101,531	7,373	34,100	9,295
31 Mar 19	94,252	5,882	32,539	9,401
31 Dec 18	91,839	3,300	31,719	10,545
30 Sep 18	88,551	9,000	29,267	10,123
30 Jun 18	89,131	9,149	27,993	12,308
31 Mar 18	87,204	6,945	27,822	11,837
31 Dec 17	84,231	5,813	27,933	9,790
30 Sep 17	85,417	3,586	27,115	11,789
30 Jun 17	81,809	562	27,597	10,210
31 Mar 17	81,807	1,355	27,941	9,386
31 Dec 16	82,882	2,026	27,660	9,003
30 Sep 16	82,223	-3,478	30,827	7,526
30 Jun 16	79,584	-5,817	32,400	6,332
31 Mar 16	79,447	-7,142	32,814	5,921
31 Dec 15	80,023	-7,077	33,227	6,066
30 Sep 15	79,818	-16,050	32,121	6,572
30 Jun 15	81,892	-13,143	31,251	6,586
31 Mar 15	81,657	-12,865	30,558	7,489
31 Dec 14	80,880	-12,658	29,786	7,795
30 Sep 14	78,763	-11,694	31,527	8,025
30 Jun 14	77,511	-17,134	32,529	9,273
31 Mar 14	76,276	-18,966	33,413	9,354
31 Dec 13	74,228	-21,499	33,682	9,507

Quality Earnings: A009420 is currently unprofitable.

Growing Profit Margin: A009420 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A009420 is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.

Accelerating Growth: Unable to compare A009420's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A009420 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).

Return on Equity

High ROE: A009420 has a negative Return on Equity (-3.67%), as it is currently unprofitable.

Hanall Biopharma Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Recent updates

Hanall Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of A First-In-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

Now 23% undervalued

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Consensus EPS estimates increase by 23%, revenue downgraded

Now 22% undervalued after recent price drop

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies